期刊
CANCERS
卷 11, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/cancers11070978
关键词
cancer; angiogenesis; tumor microenvironment; imaging; therapy
类别
资金
- Swiss National Sciences Foundation [31003A_159824/1, 31003A_179248/1]
- Swiss Cancer League [KSF3513-08-2014, KSF-4400-02-2018]
- NCCR Molecular Oncology
- NCCR Bio-Inspired materials
- Medic Foundation
- Sassella Stiftung
- 3R foundation
- European Union under FP7 collaborative project TuMIC [HEALTH-F2-2008-201662]
Correlative clinical evidence and experimental observations indicate that integrin adhesion receptors, in particular those of the alpha V family, are relevant to cancer cell features, including proliferation, survival, migration, invasion, and metastasis. In addition, integrins promote events in the tumor microenvironment that are critical for tumor progression and metastasis, including tumor angiogenesis, matrix remodeling, and the recruitment of immune and inflammatory cells. In spite of compelling preclinical results demonstrating that the inhibition of integrin alpha V beta 3/alpha V beta 5 and alpha 5 beta 1 has therapeutic potential, clinical trials with integrin inhibitors targeting those integrins have repeatedly failed to demonstrate therapeutic benefits in cancer patients. Here, we review emerging integrin functions and their proposed contribution to tumor progression, discuss preclinical evidence of therapeutic significance, revisit clinical trial results, and consider alternative approaches for their therapeutic targeting in oncology, including targeting integrins in the other cells of the tumor microenvironment, e.g., cancer-associated fibroblasts and immune/inflammatory cells. We conclude that integrins remain a valid target for cancer therapy; however, agents with better pharmacological properties, alternative models for their preclinical evaluation, and innovative combination strategies for clinical testing (e.g., together with immuno-oncology agents) are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据